Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Conditional EU Nod for Weekly Pill in Pediatric Glioma
2.
Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.
3.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
4.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
5.
Can Oncotype Predict Recurrence Risk in Older BC Patients?
1.
Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment
2.
The Science Behind Imatinib: How It Targets Cancer Cells
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
5.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
2.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge